# CORE B - Hematology, Chemistry and Coagulation Core

> **NIH NIH P01** · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · 2023 · $220,616

## Abstract

SUMMARY
Core B will provide essential support for the projects to achieve their specific aims while addressing the central
hypothesis of the program project, which is that “protein glycosylation and glycoprotein remodeling alter the
coagulopathy and inflammation of sepsis".Core B will analyze blood or plasma samples from mice, patients
with sepsis, and healthy human volunteers generated from the projects to detect any changes in the cellular
components (hematology), chemical composition (Chemistry), and hemostatic status (Coagulation) that may
take place in different experimental or clinical conditions.Core B will use defined panels of assays as an
efficient way to detect potentially significant changes in experimental versus control studies. These panels are:
1. Hematology: Complete blood count with white cell subsets (differential count) and microscopic examination
of peripheral blood smears for cellular morphology; 2. Chemistry: serum electrolytes, total protein, IgG
immunoglobulin, liver enzymes (AST, ALT, ALP), and optionally lipids (LDL, HDL, TG) to evaluate the overall
functions of the liver, pancreas, and kidney, as well as the general metabolic status; 3. Hemostasis: von
Willebrand antigen (primary hemostasis), PT, APTT, clotting factors II, V, VII, VIII, IX, X, XI and XII, fibrinogen,
and D-dimer or FDPs (coagulation), protein C, protein S, and antithrombin (anticoagulation), and antiplasmin
(fibrinolysis). Additional tests that have been standardized in Core B such as thrombin-antithrombin complex,
heparin anticoagulant activities, plasma tissue factor, tissue factor pathway inhibitor, whole blood platelet
aggregometry and whole blood thromboelastograph will be available to all projects as needed.During the past
four years, Core B has successfully used this approach to generate data of significant import to the program
including the identification of multiple differences in mouse and human blood comparing infections of discrete
pathogens implicating potential undiscovered pathways of pathogenesis with the possibility of stratification of
sepsis among both species. This proposal focuses on continuing to provide these hematological analyses of
mouse and human blood and plasma samples in support of the specific aims of the projects.

## Key facts

- **NIH application ID:** 10641840
- **Project number:** 5P01HL131474-08
- **Recipient organization:** SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
- **Principal Investigator:** Dzung T Le
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $220,616
- **Award type:** 5
- **Project period:** 2016-07-15 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10641840

## Citation

> US National Institutes of Health, RePORTER application 10641840, CORE B - Hematology, Chemistry and Coagulation Core (5P01HL131474-08). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10641840. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*